Treatment of severe erosive gingival lesions by topical application of clobetasol propionate in custom trays.
OBJECTIVE
We sought to describe the response of patients with severe erosive gingival lesions to treatment with clobetasol propionate in Orabase paste administered in trays. The adverse effects were also recorded.


METHODS
A descriptive pretest/posttest clinical study with no control group (33 patients total) was developed. All patients received repeated applications of 0.05% clobetasol propionate plus 100,000 IU/cc of nystatin in Orabase paste. Over the 48-week period, the pain levels, ulcerations, presence of atrophy, and the patients' daily activities were recorded, and Likert scales were used to classify each outcome as either a complete recovery, excellent, good, poor, or failed. The presence of any adverse effect was also noted.


RESULTS
At the end of the study period, the pain and ulceration had disappeared (complete response) in 100% of the sample (33/33; 95% confidence interval = 89.4%-100%), and there was a complete recovery of daily activities and remission of atrophy in 93.9% (31/33; 95% confidence interval = 79.8%-99.3%) and 21.2% (7/33; 95% confidence interval = 9.0%-38.9%) of the patients, respectively. No adverse effects related to the treatment were observed.


CONCLUSIONS
The application of an Orabase paste of 0.05% clobetasol 17-propionate plus 100,000 IU/cc of nystatin by means of a tray appears to be an efficacious treatment for severe erosive gingival lesions.
Gonzalez-Moles
Miguel Angel
MA
University of Granada, Jaen General Hospital, and University Complutense of Madrid, Spain. magonzal@ugr.es
Ruiz-Avila
Isabel
I
Rodriguez-Archilla
Alberto
A
Morales-Garcia
Patricia
P
Mesa-Aguado
Francisco
F
Bascones-Martinez
Antonio
A
Bravo
Manuel
M
D000203:Activities of Daily Living; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000188:drug therapy*; D002990:Clobetasol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016001:Confidence Intervals; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005882:Gingival Diseases / Q000188:drug therapy*; D005938:Glucocorticoids; D006801:Humans; D017676:Lichen Planus, Oral / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009761:Nystatin / Q000008:administration & dosage / Q000627:therapeutic use; D010147:Pain Measurement; D017060:Patient Satisfaction; D010390:Pemphigoid, Benign Mucous Membrane / Q000188:drug therapy; D013281:Stomatitis, Aphthous / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D009761:Nystatin; D002990:Clobetasol